Hairy cell leukemia (HCL) is a distinct clinicopathologic entity that responds well to purine analogs but is sometimes difficult to differentiate from HCL-like disorders (eg, splenic marginal zone lymphoma and HCL variant). We recently identified the BRAF-V600E mutation as the disease-defining genetic event in HCL. In this study, we describe a new, simple, and inexpensive test for genetics-based diagnosis of HCL in whole-blood samples that detects BRAF-V600E through a sensitive allele-specific PCR qualitative assay followed by agarose-gel electrophoresis. This approach detected BRAF-V600E in all 123 leukemic HCL samples investigated containing as few as 0.1% leukemic cells. BRAF-V600E was detected at different time points during the disease course, even after therapy, pointing to its pivotal role in HCL pathogenesis and maintenance of the leukemic clone. Conversely, 115 non-HCL chronic B-cell neoplasms, including 79 HCL-like disorders, were invariably negative for BRAF-V600E. This molecular assay is a powerful tool for improving the diagnostic accuracy in HCL. © 2012 by The American Society of Hematology.

Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation

Santi A.
;
Cecchini D.
;
Sozzi E.
;
Inghirami G.
;
2012-01-01

Abstract

Hairy cell leukemia (HCL) is a distinct clinicopathologic entity that responds well to purine analogs but is sometimes difficult to differentiate from HCL-like disorders (eg, splenic marginal zone lymphoma and HCL variant). We recently identified the BRAF-V600E mutation as the disease-defining genetic event in HCL. In this study, we describe a new, simple, and inexpensive test for genetics-based diagnosis of HCL in whole-blood samples that detects BRAF-V600E through a sensitive allele-specific PCR qualitative assay followed by agarose-gel electrophoresis. This approach detected BRAF-V600E in all 123 leukemic HCL samples investigated containing as few as 0.1% leukemic cells. BRAF-V600E was detected at different time points during the disease course, even after therapy, pointing to its pivotal role in HCL pathogenesis and maintenance of the leukemic clone. Conversely, 115 non-HCL chronic B-cell neoplasms, including 79 HCL-like disorders, were invariably negative for BRAF-V600E. This molecular assay is a powerful tool for improving the diagnostic accuracy in HCL. © 2012 by The American Society of Hematology.
2012
119
1
192
195
Case-Control Studies; DNA, Neoplasm; Flow Cytometry; Humans; Leukemia, B-Cell; Leukemia, Hairy Cell; Lymphoma, B-Cell; Point Mutation; Polymerase Chain Reaction; Proto-Oncogene Proteins B-raf; DNA Mutational Analysis
Tiacci E.; Schiavoni G.; Forconi F.; Santi A.; Trentin L.; Ambrosetti A.; Cecchini D.; Sozzi E.; Celle P.F.D.; Bello C.D.; Pulsoni A.; Foa R.; Inghirami G.; Falini B.
File in questo prodotto:
File Dimensione Formato  
Tiacci E et al.pdf

Accesso aperto

Descrizione: Articolo
Tipo di file: PDF EDITORIALE
Dimensione 492.38 kB
Formato Adobe PDF
492.38 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1823315
Citazioni
  • ???jsp.display-item.citation.pmc??? 60
  • Scopus 150
  • ???jsp.display-item.citation.isi??? 141
social impact